Short answer
K562’s extreme sensitivity to MPPE1 knockout is very plausibly a “proteostasis/secretory-pathway synthetic lethality.” MPPE1 encodes PGAP5, an ER/Golgi metallophosphoesterase that removes the ethanolamine‑phosphate side chain from Man2 of GPI anchors; this remodeling is required for p24‑mediated sorting of GPI‑anchored proteins (GPI‑APs) out of the ER. When PGAP5/MPPE1 is lost, GPI‑APs are retained in the ER, provoking ER stress and tipping the unfolded protein response (UPR) toward apoptosis. K562 already lives on a knife‑edge of ER stress and secretory load because it is BCR‑ABL–driven, p53‑defective, and carries additional hits in ER chaperoning/glycosylation genes; taking away MPPE1 pushes it over the edge. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/21727194/?utm_source=openai))

What MPPE1/PGAP5 does and what its loss causes
- Function: MPPE1 (aka PGAP5) is a dimetal phosphodiesterase that trims the EtNP side chain on Man2 of GPI anchors. This remodeling is a prerequisite for p24 cargo‑receptor engagement and efficient ER exit of GPI‑APs to the Golgi. ([ncbi.nlm.nih.gov](https://www.ncbi.nlm.nih.gov/gene/65258?utm_source=openai))
- Consequence of loss: Without PGAP5 activity, newly made GPI‑APs fail ER exit, accumulate in the early secretory pathway, and trigger ER quality‑control and UPR programs. When UPR cannot restore homeostasis, it induces apoptosis via CHOP/DR5 signaling. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/21727194/?utm_source=openai))

Why K562 is primed to be hypersensitive
- Strong oncogenic driver with high secretory load: K562 is a CML blast‑crisis line addicted to BCR‑ABL1; imatinib or ABL gene editing collapses viability. BCR‑ABL–positive leukemias show elevated PERK/eIF2α‑arm signaling and dependence on UPR/ISR buffering, so added ER burden is especially toxic. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/32485885/?utm_source=openai))
- Defective p53 fails to buffer ER stress: K562 harbors a truncating TP53 frameshift; p53 deficiency sensitizes cells to ER‑stressors such as tunicamycin and biases UPR toward cell death. Thus, an ER traffic block from MPPE1 loss is more likely to end in apoptosis. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/8246608/?utm_source=openai))
- Additional “second‑hit” variants in ER folding/glycosylation that constrain proteostasis reserve:
  - HSPA5/GRP78 (BiP) stop‑gain p.Q372Ter would eliminate the C‑terminal KDEL retrieval sequence (BiP is 654 aa), plausibly weakening ER chaperone capacity. ([assays.cancer.gov](https://assays.cancer.gov/non-CPTAC-2616?utm_source=openai))
  - GANAB (glucosidase II α) p.D494G sits in the catalytic subunit that drives the calnexin/calreticulin cycle; GANAB loss or knockdown heightens ER stress and UPR signaling. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/26676362/?utm_source=openai))
  - P4HB (protein disulfide isomerase) p.R345L hits the major ER oxidoreductase/chaperone essential for oxidative folding; perturbing PDI activity enhances UPR and reduces survival in multiple systems. ([elifesciences.org](https://elifesciences.org/articles/44528?utm_source=openai))
  - DOLK (dolichol kinase) p.S256F affects the dolichol‑phosphate supply for N‑glycosylation; DOLK defects cause congenital glycosylation disorders and sensitize cells to folding stress. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/22242004/?utm_source=openai))
  Taken together, these variants plausibly reduce the ER’s folding throughput so that PGAP5 loss (which traps GPI‑APs in the ER) becomes acutely lethal (i.e., a multi‑gene synthetic sickness/lethality). ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5800811/?utm_source=openai))
- Loss of GPI‑AP–dependent signaling tone: K562 expresses GPI‑APs such as CD59, and GPI‑AP clusters organize lipid rafts that engage Src‑family kinases (Lyn/Fyn). SFKs modulate BCR‑ABL signaling outputs in myeloid cells. Blocking GPI‑AP trafficking via MPPE1 loss may blunt this pro‑survival membrane signaling context. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/7543447/?utm_source=openai))

How this fits the dependency profile you see
- Your top dependencies include ABL1, BCR and GAB2, consistent with BCR‑ABL addiction. MPPE1 appearing alongside these suggests a lineage/contextual “core secretory” liability in K562. Because MPPE1 sits upstream of surface display for many GPI‑APs, it can act as a choke‑point: its loss simultaneously increases ER misfolded‑protein load and removes raft‑resident co‑receptors/modulators, both of which are poorly tolerated in BCR‑ABL+, TP53‑mutant, ER‑fragile cells. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/32485885/?utm_source=openai))

Variant‑level notes from your list that are most mechanistically relevant
- TP53 insertion frameshift p.Q136PfsTer13 (loss of WT p53 buffering of ER stress). ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/8246608/?utm_source=openai))
- HSPA5 stop‑gain p.Q372Ter (predicts loss of KDEL retrieval; BiP is 654 aa and needs C‑terminal KDEL for ER residency). ([assays.cancer.gov](https://assays.cancer.gov/non-CPTAC-2616?utm_source=openai))
- GANAB p.D494G (central to calnexin/calreticulin folding cycle; GANAB depletion induces ER stress). ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/26676362/?utm_source=openai))
- P4HB p.R345L (ER oxidative folding hub; PDI perturbation activates UPR and reduces viability). ([elifesciences.org](https://elifesciences.org/articles/44528?utm_source=openai))
- DOLK p.S256F (N‑glycosylation lipid donor synthesis; DOLK defects cause glycosylation insufficiency). ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/22242004/?utm_source=openai))
Caveat: individual missense effects are context‑ and zygosity‑dependent; the argument is that the aggregate burden on ER proteostasis is high in K562, making MPPE1 loss catastrophic.

Quick experiments to validate the mechanism in your lab
- Confirm failure of GPI‑AP surface display after MPPE1 KO: flow cytometry with FLAER and antibodies to CD55/CD59. Expect strong loss of FLAER/CD59 signal post‑KO. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/10989647/?utm_source=openai))
- Check ER‑stress/UPR and DR5‑axis engagement after MPPE1 KO: ATF4/CHOP induction, spliced XBP1, and DR5 accumulation with caspase‑8 activation. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/24994655/?utm_source=openai))
- Chemical rescue: partial rescue of viability by chemical chaperones (4‑PBA or TUDCA) would support “proteostasis‑overload” as the proximal cause. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/23336977/?utm_source=openai))
- Genetic rescue: re‑express WT PGAP5/MPPE1 (but not a catalytically dead mutant) to restore GPI‑AP export and viability. The catalysis requirement follows from PGAP5’s role in ER‑exit remodeling. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/19837036/?utm_source=openai))
- Context tests: reduce ER load (e.g., brief BCR‑ABL inhibition) and ask whether MPPE1‑KO lethality is partially mitigated; conversely, augment ER stress (tunicamycin/Thapsigargin) to see supra‑additive toxicity. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/23095523/?utm_source=openai))

Bottom line
MPPE1/PGAP5 is an early secretory‑pathway gatekeeper for GPI‑APs. In K562—a BCR‑ABL–driven, TP53‑mutant line with additional hits in ER folding/glycosylation—blocking this gate overloads the ER and removes membrane GPI‑AP signaling support at the same time. That double hit explains why MPPE1 knockout is unusually lethal in this background. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/21727194/?utm_source=openai))

References (selected)
- PGAP5 biology and ER‑exit of GPI‑APs: Fujita et al., J Cell Biol 2009; Fujita et al., J Cell Biol 2011; NCBI Gene MPPE1. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/19837036/?utm_source=openai))
- UPR/ER‑stress linkage to apoptosis: Lu et al., Science 2014. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/24994655/?utm_source=openai))
- UPR in leukemia and BCR‑ABL context: Schewe et al., Leukemia 2021; Higa et al., 2012; Dong et al., 2018. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/33573353/?utm_source=openai))
- K562/BCR‑ABL dependence: Wang et al., Cancers (Basel) 2020 (CRISPR ABL editing); additional K562 background. ([mdpi.com](https://www.mdpi.com/2072-6694/12/6/1399?utm_source=openai))
- K562 TP53 frameshift: McConnell et al., 1993. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/8246608/?utm_source=openai))
- ER chaperones/glycosylation roles (HSPA5, GANAB, P4HB, DOLK): reviews and functional papers cited above. ([assays.cancer.gov](https://assays.cancer.gov/non-CPTAC-2616?utm_source=openai))
- K562 expresses GPI‑APs (e.g., CD59): Morgan et al., 1995. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/7543447/?utm_source=openai))
- Lipid‑raft/Src signaling by GPI‑APs: numerous mechanistic studies. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC60153/?utm_source=openai))

If helpful, I can map each of your listed variants onto ER‑proteostasis pathways and sketch a minimal experimental panel (guides, antibodies, and readouts) to test this model end‑to‑end.